BioCryst Pharmaceuticals (BCRX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.27
- Estimate
- $0.12
- Surprise
- +131.1%
- Revenue (period 2026-09-30)
- $180.3M
- Score today
- 7.4/10
Revenue source: xbrl.
How the report landed
BioCryst Pharmaceuticals (BCRX) beat the $0.12 estimate with adjusted EPS of $0.27 — a large 131.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BCRX Buy (Wait) at 7.4/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +131.1% surprise compares with a +101.4% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- RISK-OFF: SMALL-cap BUY_NOW needs quality>=8.5 or MoS>=50%
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.24
- Entry target
- $7.87
- Price target
- $17.87
- Stop
- $7.32
- Upside to target
- +116.9%
- Reward-to-risk
- 13.4:1
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
BCRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.11B
- P/E (fwd)
- 10.0
- 52-week range
- $6.23–$11.22
- Off 52-week high
- 26.6%
- RSI (14)
- 54
- Volume vs avg
- 1.94×
- Score today
- 7.4/10